GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (NAS:YMTX) » Definitions » ROA %

Yumanity Therapeutics (Yumanity Therapeutics) ROA % : -107.41% (As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Yumanity Therapeutics's annualized Net Income for the quarter that ended in Sep. 2022 was $-13.45 Mil. Yumanity Therapeutics's average Total Assets over the quarter that ended in Sep. 2022 was $12.52 Mil. Therefore, Yumanity Therapeutics's annualized ROA % for the quarter that ended in Sep. 2022 was -107.41%.

The historical rank and industry rank for Yumanity Therapeutics's ROA % or its related term are showing as below:

YMTX's ROA % is not ranked *
in the Biotechnology industry.
Industry Median: -35.42
* Ranked among companies with meaningful ROA % only.

Yumanity Therapeutics ROA % Historical Data

The historical data trend for Yumanity Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics ROA % Chart

Yumanity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
ROA %
-177.26 -86.81 -44.44

Yumanity Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.72 -62.74 -113.29 -82.42 -107.41

Competitive Comparison of Yumanity Therapeutics's ROA %

For the Biotechnology subindustry, Yumanity Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yumanity Therapeutics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where Yumanity Therapeutics's ROA % falls into.



Yumanity Therapeutics ROA % Calculation

Yumanity Therapeutics's annualized ROA % for the fiscal year that ended in Dec. 2021 is calculated as:

ROA %=Net Income (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=-39.503/( (114.835+62.932)/ 2 )
=-39.503/88.8835
=-44.44 %

Yumanity Therapeutics's annualized ROA % for the quarter that ended in Sep. 2022 is calculated as:

ROA %=Net Income (Q: Sep. 2022 )/( (Total Assets (Q: Jun. 2022 )+Total Assets (Q: Sep. 2022 ))/ count )
=-13.452/( (15.469+9.579)/ 2 )
=-13.452/12.524
=-107.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2022) net income data. ROA % is displayed in the 30-year financial page.


Yumanity Therapeutics  (NAS:YMTX) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2022 )
=Net Income/Total Assets
=-13.452/12.524
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-13.452 / 5.608)*(5.608 / 12.524)
=Net Margin %*Asset Turnover
=-239.87 %*0.4478
=-107.41 %

Note: The Net Income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Yumanity Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Yumanity Therapeutics (Yumanity Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
40 Guest Street, Suite 4410, Boston, MA, USA, 02135
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.
Executives
Shawn Iadonato director, officer: Chief Executive Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips officer: President C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Raymond J. Bartoszek director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker officer: Chief Financial Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny officer: General Counsel C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux officer: Chief Scientific Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Richard Peters director, officer: President & CEO MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Devin Whittemore Smith officer: SVP and General Counsel C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Marie Epstein officer: Principal Accounting Officer C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Michael D Wyzga officer: See Remarks C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Paulash Mohsen officer: Chief Business Officer C/O YUMANITY THERAPEUTICS, INC., 40 GUESS STREET SUITE 4410, BOSTON MA 02135
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma officer: EVP, Head of R&D C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
N Anthony Coles director, officer: Executive Chair MORRIS CORP. CENTER I; BLDG. B; 4TH FLR., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054